Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Wed Apr 02 15:23:34 GMT 2025
by
admin
on
Wed Apr 02 15:23:34 GMT 2025
|
| Protein Type | FUSION PROTEINS |
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
X8K6U56JL4
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
855021
Created by
admin on Wed Apr 02 15:23:34 GMT 2025 , Edited by admin on Wed Apr 02 15:23:34 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
X8K6U56JL4
Created by
admin on Wed Apr 02 15:23:34 GMT 2025 , Edited by admin on Wed Apr 02 15:23:34 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET->LIGAND |
Fusion protein that binds HDM2 on cancer cells and leads to lysis of cell. p53-independent HDM2 expression has been reported on the membrane of cancer cells but not on that of normal cells. Herein, we first showed that membrane HDM2 (mHDM2) is exclusively expressed on human and mouse AML blasts, including leukemia stem cell (LSC)-enriched subpopulations, but not on normal hematopoietic stem cells (HSCs).
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Fusion protein
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|
||||
| Molecular Formula | CHEMICAL |
|